Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an international compassionate use study

Cancer

Volumn 98, Issue 5, 2003, Pages 1048-1054

  Bosly, André ^a   Sonet, Anne ^a   Pinkerton, C Ross ^b   McCowage, Geoffrey ^c   Bron, Dominique ^d   Sanz, Miguel A ^e   Van den Berg, Hendrik ^f  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d JULES BORDET INSTITUTE   (Belgium)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Acute leukemia; Compassionate use; Hemodialysis; Hyperuricemia; Non Hodgkin lymphoma; Rasburicase (Fasturtec Elitek ); Tumor lysis syndrome

Indexed keywords

ALLOPURINOL; RASBURICASE; URIC ACID;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GOUT; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HUMAN; HYPERURICEMIA; HYPOCALCEMIA; INFANT; LEUKEMIA; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METHEMOGLOBINEMIA; PRIORITY JOURNAL; RIGOR; SOLID TUMOR; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERURICEMIA; INFANT; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 0041887047     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11612     Document Type: Article

References (23)

1. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.
2. Bishop MR, Coccia PF. Tumor lysis syndrome. In: Abeloff MD, editor. Clinical oncology (2nd edition). New York: Churchill Livingstone, 2000:750-754.
3. Altman A. Acute tumor lysis syndrome. Semin Oncol. 2001;28(2 Suppl 5):3-8.
4. Sallan S. Management of acute tumor lysis syndrome. Semin Oncol. 2001;28:9-12.
5. Smalley RV, Guaspari A, Haase-Statz S, et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000;18:1758-1763.
6. Zyloric. Summary of product characteristics [monograph online]. Available from URL: http://emc.vhn.net/eMC/assets/c/html/Displaydoc.asp?document.ID=4565 [accessed 10 July, 20031.
7. Band PR, Silverberg DS, Henderson JF, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 1970;283:354-357.
8. Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr. 1986;109:292-298.
9. Masera G, Jankovic M, Zurlo MG, et al. Urate-oxidase prophylaxis of uric acid-induced renal damage in children. J Pediatr. 1982;100:152-155.
10. Leach M, Parsons RM, Reilly JT, et al. Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol. 1998;20:169-172.
11. Brogard JM, Coumaros D, Franckhauser J, et al. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol. 1972;17:890-895.
12. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol. 2002;13:789-795.
13. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prohylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19:697-704.
14. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15:1505-1509.
15. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase, Elitek) for prevention and treatment of malignancy-associated hyperuricemia: updated results of a compassionate use trial [abstract]. Blood 2002;100(11 Suppl 1):556a.
16. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813-1816.
17. Coiffier B, Mounier N, Bologna S, et al. Final results of the efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia in patients with aggressive lymphoma (GRAAL 1 study) [abstract]. Blood 2002;100(11 Suppl 1):359a.
18. Dann EJ, Fineman R, Rowe JM. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Oncol. 2002;20:354-355.
19. Vora A, Bhutani M, Sharma A, et al. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol. 2002;13:1833-1834.
20. Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 1998;77:89-91.
21. Yang H, Rosove MH, Figlin RA, et al. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol. 1998;62:247-250.
22. Anderson S, Files J. Tumor lysis syndrome secondary to gemtuzumab ozogamicin in a patient with acute myelogenous leukemia. J Miss State Med Assoc. 2002;43:105-106.
23. Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother. 2002;3:433-452.